Patents by Inventor Casey Jacobs
Casey Jacobs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220127247Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.Type: ApplicationFiled: February 4, 2020Publication date: April 28, 2022Inventors: Mihai AZIMIOARA, Bei CHEN, Robert EPPLE, James Paul LAJINESS, Casey Jacob Nelson MATHISON, Juliet NABAKKA, Victor Ivanovich NIKULIN, Sejal PATEL, Dean Paul PHILLIPS, Paul Vincent RUCKER, Andrew VALIERE, Baogen WU, Shanshan YAN, Xuefeng ZHU
-
Publication number: 20220071971Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.Type: ApplicationFiled: December 18, 2019Publication date: March 10, 2022Inventors: Mihai Azimioara, Badry Bursulaya, Songchun Jiang, Casey Jacob Nelson MATHISON, Victor Ivanovich NIKULIN, Truc Ngoc NGUYEN, Barun OKRAM, Sejal PATEL, Dean Paul PHILLIPS, Lewis WHITEHEAD, Baogen WU, Shanshan YAN, Xuefeng ZHU
-
Publication number: 20210369716Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: ApplicationFiled: August 10, 2021Publication date: December 2, 2021Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
-
Patent number: 11123348Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: February 3, 2020Date of Patent: September 21, 2021Assignee: Novartis AGInventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
-
Patent number: 11066369Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.Type: GrantFiled: September 10, 2019Date of Patent: July 20, 2021Assignee: Novartis AGInventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, True Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
-
Publication number: 20200179391Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: ApplicationFiled: February 3, 2020Publication date: June 11, 2020Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
-
Patent number: 10596175Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: August 29, 2018Date of Patent: March 24, 2020Assignee: Novartis AGInventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
-
Publication number: 20200002281Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.Type: ApplicationFiled: September 10, 2019Publication date: January 2, 2020Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, Truc Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
-
Patent number: 10450273Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.Type: GrantFiled: August 28, 2017Date of Patent: October 22, 2019Assignee: Novartis AGInventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, Truc Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
-
Publication number: 20190000852Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: ApplicationFiled: August 29, 2018Publication date: January 3, 2019Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
-
Patent number: 10085989Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: May 19, 2017Date of Patent: October 2, 2018Assignee: Novartis AGInventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
-
Publication number: 20170333437Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: ApplicationFiled: May 19, 2017Publication date: November 23, 2017Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh Nagle, Frantisek SUPEK, Vince YEH
-
Patent number: 9700559Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: February 23, 2016Date of Patent: July 11, 2017Assignee: Novartis AGInventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
-
Publication number: 20160303129Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: ApplicationFiled: February 23, 2016Publication date: October 20, 2016Applicant: NOVARTIS AGInventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh Nagle, Frantisek SUPEK, Vince YEH
-
Patent number: 9303034Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: December 18, 2014Date of Patent: April 5, 2016Assignee: Novartis AGInventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
-
Patent number: 9233961Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.Type: GrantFiled: March 13, 2014Date of Patent: January 12, 2016Assignees: Novartis AG, University of Washington through its Center for CommercializationInventors: Arnab Kumar Chatterjee, Fang Liang, Casey Jacob Nelson Mathison, Pranab Kumar Mishra, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Liying Jocelyn Tan, Agnes Vidal, Michael Herman Gelb, Frederick Simmons Buckner, Hari Babu Tatipaka, Neil Richard Norcross, John Robert Gillespie
-
Patent number: 9186361Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.Type: GrantFiled: March 13, 2014Date of Patent: November 17, 2015Assignee: Novartis AGInventors: Arnab Kumar Chatterjee, Fang Liang, Casey Jacob Nelson Mathison, Pranab Kumar Mishra, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Liying Jocelyn Tan, Agnes Vidal
-
Publication number: 20150175613Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: ApplicationFiled: December 18, 2014Publication date: June 25, 2015Applicant: IRM LLCInventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
-
Publication number: 20140274926Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: IRM LLCInventors: Arnab Kumar CHATTERJEE, Fang LIANG, Casey Jacob Nelson MATHISON, Pranab Kumar MISHRA, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Liying Jocelyn TAN, Agnes VIDAL
-
Publication number: 20140275013Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicants: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, IRM LLCInventors: Arnab Kumar CHATTERJEE, Fang LIANG, Casey Jacob Nelson MATHISON, Pranab Kumar MISHRA, Valentina MOLTENI, Advait Suresh Nagle, Frantisek SUPEK, Liying Jocelyn TAN, Agnes VIDAL, Michael Herman GELB, Frederick Simmons BUCKNER, Hari Babu TATIPAKA, Neil Richard NORCROSS, John Robert GILLESPIE
